{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cass SH"],"funding":["NCI NIH HHS"],"pagination":["796-805"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11289780"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(9)"],"pubmed_abstract":["Background
Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing malignancies. Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia and is associated with increased risk of melanoma. CLL alters systemic immunity and can induce T-cell exhaustion, which may limit the efficacy of ICIs in patients with CLL. We, therefore, sought to examine the efficacy of ICI in patients with these co-occurring diagnoses.Patients and methods
In this international multicenter study, a retrospective review of clinical databases identified patients with concomitant diagnoses of CLL and AM treated with ICI (US-"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia."],"pmcid":["PMC11289780"],"funding_grant_id":["P50 CA221703","R25 CA203650","R01 CA219896"],"pubmed_authors":["Millward M","McQuade JL","Sandhu S","Lazar AJ","Cass SH","Tobin JWD","Gener-Ricos G","Wargo JA","Keung EZ","Ding W","Parikh SA","Markovic SN","Burgess M","Keane C","Smith JL","Mapp S","Menzies AM","Dearden H","Mason R","Burton EM","Guerra V","Haydon A","Mollee P","Khoo C","Seo YD","Ferrajoli A","Carlino MS","Hampel PJ","Long GV","Davies MA","Warburton L","Atkinson V","Call TG"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.","description":"Background
Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing malignancies. Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia and is associated with increased risk of melanoma. CLL alters systemic immunity and can induce T-cell exhaustion, which may limit the efficacy of ICIs in patients with CLL. We, therefore, sought to examine the efficacy of ICI in patients with these co-occurring diagnoses.Patients and methods
In this international multicenter study, a retrospective review of clinical databases identified patients with concomitant diagnoses of CLL and AM treated with ICI (US-","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-04-18T21:42:53.862Z","creation":"2025-02-19T02:34:51.608Z"},"accession":"S-EPMC11289780","cross_references":{"pubmed":["37414216"],"doi":["10.1016/j.annonc.2023.06.007"]}}